AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01049165
Drug: [14C] BMS-813160
DrugBank: BMS-813160 (DB16240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 150 mg, Single Dose, 1 day
Trial: NCT01049165
Drug: BMS-813160
RxNorm normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 1200 mg, Single dose, 1 day
Trial: NCT01049165
Drug: BMS-813160
RxNorm normalized name: BMS-813160
DrugBank: BMS-813160 (DB16240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 2000 mg, Single Dose, 1 day
Trial: NCT00373165
Drug: Ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00024427
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Normal dose to treat pancreatic cancer
Trial: NCT00024427
Drug: triacetyluridine
RxNorm normalized name: Triacetyluridine
DrugBank: Uridine triacetate (DB09144)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6 grams (12 tablets)
Trial: NCT04088448
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fluoxetine 20 mg capsule plus Metformin 1000 mg extended release tablet administered once daily after food
Trial: NCT02862691
Drug: Bupivicaine (Injectable local anesthetic)
RxNorm normalized name: Gelato Anesthetic
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
Trial: NCT00359944
Drug: AC-3933
RxNorm normalized name: Ac
DrugBank: Actinium (DB12860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg twice daily
Trial: NCT00359944
Drug: AC-3933
RxNorm normalized name: Ac
DrugBank: Actinium (DB12860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC-3933, 20 mg twice daily
Trial: NCT00003234
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003103
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00521430
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00521430
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00521430
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00521430
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00585221
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Continue imatinib until progression.
Trial: NCT00068250
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2, intravenously three days prior to the first cycle of methotrexate
Trial: NCT00068250
Drug: temozolomide 100 mg/m^2
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 100 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
Trial: NCT00068250
Drug: temozolomide 150 mg/m^2
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 150 mg/m\^2 by mouth per day for five days on weeks 4 and 8.
Trial: NCT00068250
Drug: temozolomide 200 mg/m^2
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide 200 mg/m\^2 per day by mouth for five days on weeks 4 and 8.
Trial: NCT00068250
Drug: post-radiation therapy temozolomide
RxNorm normalized name: lidocaine
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide (TMZ) 200 mg/m\^2 by mouth per day for 5 days on weeks 14, 18, 22, 26, 30, 34, 38, 42, 46, and 50 for a total of 10 cycles.
Trial: NCT00620425
Drug: Sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection
Trial: NCT01824823
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT00895414
Drug: enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
Trial: NCT00000146
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000146
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00420615
Drug: Patupilone and Omeprazole
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00420615
Drug: Patupilone + Midalzolam
RxNorm normalized name: Midazolam
DrugBank: Patupilone (DB03010)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03342573
Drug: Cosentyx
RxNorm normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cosentyx 300 mg SQ week 0-4, then every q4 weeks for a total of 28 weeks.
Trial: NCT03404804
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral challenge with amoxicillin in patients who are deemed low-risk for true penicillin allergy
Trial: NCT02956044
Drug: Bexagliflozin
RxNorm normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bexagliflozin tablets, 20 mg
Trial: NCT02956044
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1000 mg metformin
Trial: NCT02956044
Drug: Glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg glimepiride
Trial: NCT02956044
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg sitagliptin
Trial: NCT00559468
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose 4.0 mg/kg sugammadex, administered at T1 3-10% after continuous infusion of rocuronium
Trial: NCT00559468
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single bolus dose 0.6 mg/kg rocuronium and continuous infusion rocuronium
Trial: NCT00559468
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane IV administered for induction and maintenance of anesthesia, based on randomization.
Trial: NCT00559468
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol IV administered for induction and maintenance of anesthesia, based on randomization.
Trial: NCT01593995
Drug: Epidermal growth factor (EGF) ointment
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect
Trial: NCT00679458
Drug: buprenorphine alone
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
Trial: NCT00931723
Drug: Quetiapine fumarate XR
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
Trial: NCT00931723
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
Trial: NCT01414101
Drug: ISIS CRP Rx or Placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01165112
Drug: Bendamustine Hydrochloride
RxNorm normalized name: Bendamustine Hydrochloride
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01165112
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01165112
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03937648
Drug: COL-144 50mg
RxNorm normalized name: Col-118
DrugBank: Col-118 (DB05778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL-144 50mg
Trial: NCT03937648
Drug: COL-144 100mg
RxNorm normalized name: Col-118
DrugBank: Col-118 (DB05778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL-144 100mg
Trial: NCT03937648
Drug: COL-144 200mg
RxNorm normalized name: Col-118
DrugBank: Col-118 (DB05778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL-144 200mg
Trial: NCT03937648
Drug: COL-144 400mg
RxNorm normalized name: Col-118
DrugBank: Col-118 (DB05778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COL-144 400mg
Trial: NCT01683006
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous application of Rocuronium (0.5 mg/kg body weight/hour).~Bolus application of placebo in case of shivering.
Trial: NCT04600505
Drug: Treatment C
RxNorm normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 inhalations of BGF MDI with HFA propellant.
Trial: NCT01518998
Drug: Fimasartan , Amlodipine, Placebo
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
Trial: NCT01926171
Drug: Icotinib plus WBRT
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
Trial: NCT02250807
Drug: Simeprevir
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
Trial: NCT02250807
Drug: Sofosbuvir
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
Trial: NCT04073784
Drug: Gemcitabine combined with Aptinib and Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine injection, gemcitabine 1000mg/m2, Day 1 and Day 8 of each 21 day, maximum 6 cycles.~Apatinib for oral administration, 250mg, once a day. Apatinib maintenance.~Toripalimab injection, 240mg, Day 1 each 21day. Toripalimab maintenance.
Trial: NCT00199316
Drug: spinal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03876015
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Trial: NCT00907803
Drug: ST-246 400 mg
RxNorm normalized name: STS
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, 400 mg daily for 14 days
Trial: NCT00907803
Drug: ST-246 600 mg
RxNorm normalized name: STS
DrugBank: Tecovirimat (DB12020)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, 600 mg daily for 14 days
Trial: NCT01010568
Drug: Ofatumumab and Bendamustine
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
Trial: NCT03510468
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each tablet contains 25 mg of tenofovir alafenamide.
Trial: NCT03510468
Drug: Rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each tablet contains 150 mg of rifapentine. Participants who weigh 45 to \< 50 kg will take 750 mg (5 tablets), and participants who weigh (Bullet) 50 kg will take 900 mg (6 tablets).
Trial: NCT03510468
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each tablet is formulated as 100 or 300 mg of isoniazid.
Trial: NCT02995083
Drug: 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
Trial: NCT02995083
Drug: Air 10 ml
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
Trial: NCT00888355
Drug: losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
Trial: NCT01448824
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04618042
Drug: FX06
RxNorm normalized name: FX06
DrugBank: FX06 (DB05685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FX06 i.v.: 400 mg per day (divided in two injections) during 5 days
Trial: NCT04618042
Drug: Placebo of FX06
DrugBank: FX06 (DB05685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo i.v.: 400 mg per day (divided in two injections) during 5 days
Trial: NCT00713921
Drug: Fesoterodine Oral Product
RxNorm normalized name: fesoterodine Oral Product
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After urological and neurological evaluation, those patients who meet he US approved indications for prescribing will be placed on a regimen of Toviaz 4 mg/day taken once daily with liquids and swallowed whole. The Toviaz dose may be increased to 8 mg/day if there is not therapeutic response on the 4 mg/day.
Trial: NCT04067037
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Trial: NCT04067037
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Trial: NCT04067037
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Trial: NCT04067037
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 375mg/m2, Intravenous administration on day 1 and day 15 of each 4-week cycle until disease progression or unacceptable toxicity develops, up to 6 cycles.
Trial: NCT04656795
Drug: MT-7117
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-7117
Trial: NCT03633630
Drug: Amla
RxNorm normalized name: Amlactin
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Trial: NCT03711929
Drug: DE-109 Intravitreal Injections
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 440 ug of DE-109 Injectable Solution
Trial: NCT03711929
Drug: DE-109 Intravitreal Injections
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Undisclosed Fixed Dose of DE-109 Injectable Solution (range of 44 ug to 880 ug)
Trial: NCT03711929
Drug: DE-109 Intravitreal Injections (Open Label)
RxNorm normalized name: DES
DrugBank: Diethylstilbestrol (DB00255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After double-masked treatment period (injections every 2 months), eligible subjects would enter the open-labeled period and had DE-109 440 ug injections every 2 months (Month 6, Month 8, and Month 10)
Trial: NCT03723538
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients undergoing tracheal resection and reconstruction surgery were enrolled in this prospective observational pilot study to evaluate dexmedetomidine-based sedation after tracheal surgery in an Intensive Care Unit (ICU). Patients remain electively intubated with an uncuffed nasal endotracheal tube, awake and exhibit spontaneous breathing The neck was maintained in flexion through chin-to-chest sutures. Infusion of dexmedetomidine was started from a dosage of 0.7 μg kg-1 h-1 followed by dose titration to the target level of the sedation Richmond Agitation Sedation Scale, (RASS) score -1/-2 using a dose range of 0.2-1.4 μg kg-1 h-1.
Trial: NCT00408655
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00408655
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00408655
Drug: temsirolimus
RxNorm normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given IV
Trial: NCT02830347
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extraction
Trial: NCT00539513
Drug: N-Acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
Trial: NCT00004206
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00100230
Drug: docosahexaenoic acid OR corn/soy oil placebo
DrugBank: Corn (DB10572)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
Trial: NCT03245736
Drug: Tisotumab Vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
Trial: NCT02427568
Drug: MDMA (125 mg)
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sessions of MDMA (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
Trial: NCT00929188
Drug: JNJ-42160443
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
Trial: NCT02994953
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received avelumab intravenous (IV) infusion once a week on Day 1 and Day 15 of each cycle.
Trial: NCT02994953
Drug: M9241
RxNorm normalized name: Moxidectin
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants received Subcutaneous (SC) injection of M9241 in escalating doses on Day 1 of each cycle.